Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

February 28, 2017

Primary Completion Date

September 30, 2020

Study Completion Date

January 31, 2021

Conditions

Primary Sclerosing CholangitisInflammatory Bowel Disease

Interventions

DRUG

Vedolizumab

Vedolizumab intravenous infusion

DRUG

Placebo